Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology | Family Medicine
Disease Category: Kidney Cancer
Location: United States, CA
SWOG S0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning. The current standard treatment after surgery is careful monitoring with no immediate treatment. Studies suggest that one way kidney cancer may grow is through chemical signaling through a protein named “mTOR.” Everolimus is a drug that stops signaling through mTOR and may therefore inhibit (slow down or stop) the growth of kidney cancer. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer. It is considered investigational for use after surgery.
You are being asked to take part in this study because you have cancer of the kidney that has been surgically removed.
In this study, you will get either everolimus or placebo (a pill with no medication). You will not get both.
Patient Inclusion/Exclusion Criteria:
- See http://clinicaltrials.coh.org for additional information.
City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)
Research Center Information: City of Hope
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these